Home » Health » Clinical trials of the drug to treat coronavirus begin at the University of Nebraska medical center

Clinical trials of the drug to treat coronavirus begin at the University of Nebraska medical center

A clinical trial for a drug to treat COVID-19, or coronavirus, has started at the University of Nebraska Medical Center. The regulatory sponsor of the trial is the National Institute of Allergies and Infectious Diseases, part of the National Institutes of Health. This is the first clinical study in the United States to evaluate an experimental treatment for COVID-19, the respiratory disease first detected in December 2019 in Wuhan, Hubei province, China. The randomized controlled clinical trial of experimental antiviral remdesivir is being tested by hospitalized adults diagnosed with coronavirus. Remdesivir is an experimental broad spectrum antiviral treatment. The first participant in the trial is an American who was brought to Omaha after being quarantined on the Diamond Princess cruise ship that docked in Yokohama, Japan, and volunteered to participate in the study. There are no specific therapies approved by the Food and Drug Administration (FDA) to treat people with COVID-19. As of February 24, the World Health Organization (WHO) has reported 77,262 confirmed cases of COVID-19 and 2,595 deaths in China and 2,069 cases of COVID-19 and 23 deaths in 29 other countries. There were 14 confirmed cases of COVID-19 reported in the United States and another 39 cases among people repatriated to the United States, according to the Centers for Disease Control and Prevention (CDC) .Dr. Andre Kalil, the infectious disease specialist and professor of internal medicine who is conducting the first clinical trial for the first drug to treat COVID-19, spoke to the media and answered the questions in the video below: Kalil said that the goal of the study is to test 400 patients. Patients will receive the drug within 72 hours of diagnosis. The process will be international but it is starting in Nebraska. Half of the patients will be given the drug and half will be given a placebo. “We should have the results in a year or less … at least the preliminary results,” he said. “To be on probation, they must be slightly sicker than a mild disease,” Kalil said, adding that candidates should have pneumonia in the lungs or lung infection. “The goal here is to help people who need it most,” he said.

A clinical trial for a drug to treat COVID-19, or coronavirus, has started at the University of Nebraska Medical Center.

The regulatory sponsor of the process is the National Institute of Allergies and Infectious Diseases, part of the National Institutes of Health. This is the first clinical study in the United States to evaluate an experimental treatment for COVID-19, the respiratory disease first detected in December 2019 in Wuhan, Hubei province, China.

The randomized controlled clinical trial of experimental antiviral remdesivir is being tested by hospitalized adults diagnosed with coronavirus. Remdesivir is an experimental broad spectrum antiviral treatment.

The first participant in the trial is an American who was brought to Omaha after being quarantined on the Diamond Princess cruise ship which docked in Yokohama, Japan, and volunteered to participate in the study.

There are no specific therapies approved by the Food and Drug Administration (FDA) to treat people with COVID-19.

As of February 24, the World Health Organization (WHO) has reported 77,262 confirmed cases of COVID-19 and 2,595 deaths in China and 2,069 cases of COVID-19 and 23 deaths in 29 other countries. There were 14 confirmed cases of COVID-19 reported in the United States and 39 other cases among people repatriated to the United States, according to the Centers for Disease Control and Prevention (CDC).

Dr. Andre Kalil, infectious disease specialist and professor of internal medicine who is conducting the first clinical trial for the first drug to treat COVID-19, spoke to the media and answered the questions in the video below:

Kalil said that the goal of the trial is to test 400 patients. Patients will receive the drug within 72 hours of diagnosis.

The process will be international but it is starting in Nebraska. Half of the patients will be given the drug and half will be given a placebo.

“We should have the results in a year or less … at least the preliminary results,” he said.

“To be on the test, they must be slightly sicker than a mild disease,” Kalil said, adding that candidates should have pneumonia in the lungs or lung infection.

“The goal here is to help people who need it most,” he said.

.

Leave a Comment